Highlight
This first randomized controlled trial (RCT) assessing corticosteroid therapy in ethambutol-induced optic neuropathy (EtON) demonstrates that high-dose intravenous methylprednisolone (IVMP) significantly improves the proportion of patients with visual acuity gain and enhances visual field parameters compared to placebo. Importantly, no serious adverse events were reported with IVMP administration. These findings suggest a potentially effective intervention for a condition traditionally managed only by drug discontinuation.
Study Background and Disease Burden
Specialty calculators
For clinical reference; use professional judgment.
